

The following listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-10. (Cancelled):

11. (Previously Presented): A method according to claim 34, wherein said LHRH analogue is an LHRH agonist.

12. (Previously Presented): A method according to claim 34, wherein said LHRH analogue is Leuprorelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>, Ramorelix, or Zoladex.

13. (Previously Presented): A method according to claim 34, wherein said one or more LHRH analogues is orally bioavailable.

14. (Previously Presented): A method according to claim 34, wherein said one or more LHRH analogues is a non-peptidergic LHRH agonist or non-peptidergic LHRH antagonist.

Claims 15-19. (Cancelled):

20. (Previously Presented): A method according to claim 34, wherein said LHRH analogue is an LHRH antagonist.

Claims 21-29. (Cancelled):

30. (Previously Presented): A method according to claim 34, wherein said LHRH analogue is administered in the amount of 2 µg-20 mg per kilogram of body weight and Raloxifen is administered in an amount of 0.1 µg-10 mg per kilogram of body weight.

33. (Previously Presented): A method according to claim 34, wherein said LHRH analogue is peptidergic.

34. (Previously Presented): A method for ameliorating LHRH analogue-induced reduction in bone density in a patient comprising administering to said patient one or more LHRH analogues and Raloxifen wherein said one or more LHRH analogues and Raloxifen are administered sequentially or simultaneously.

35. (Previously Presented): A method according to claim 34, wherein said LHRH analogue is Leuporelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>, Ramorelix, Zoladex or combinations thereof.

36. (Previously Presented): A method according to claim 34, wherein Raloxifen is administered after administration of said LHRH analogue.

Claims 37-39. (Cancelled):

40. (Previously Presented): A method according to claim 34, wherein said LHRH analogue is Leuporelin, Cetrorelix, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>, Ramorelix, or Zoladex.

41. (Cancelled):

42. (Currently Amended): A method according to claim 40 ~~41~~, wherein said LHRH analogue is Antide.

43. (Currently Amended): A method according to claim 40 ~~41~~, wherein said LHRH analogue is Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>.

44. (Previously Presented): A method of inhibiting LHRH analog-induced detrimental side effects due to the administration of an LHRH analog to a patient, wherein said detrimental side effect is reduction in bone density, comprising administering to a patient in need thereof an effective amount of Raloxifen.

45. (Previously Presented): A method according to claim 44, wherein said patient is a woman.

46. (Previously Presented): A method according to claim 45, wherein Raloxifen is administered orally.

47. (Previously Presented): A method according to claim 44, wherein said LHRH analog is Leuprorelin, Buserelin or Zoladex.

Claims 48-50. (Cancelled):

51. (Previously Presented): A method for ameliorating LHRH analogue-induced reduction in bone density in a patient comprising administering to said patient one or more LHRH analogues and Raloxifen or the hydrochloride salt thereof wherein said one or more LHRH analogues and Raloxifen, or the hydrochloride salt, are administered sequentially or simultaneously.

52. (Previously Presented): A method of inhibiting LHRH analog-induced detrimental side effects due to the administration of an LHRH analog to a patient, wherein said detrimental side effect is reduction in bone density, comprising administering to a patient in need thereof an effective amount of Raloxifen or the hydrochloride salt thereof.

53. (Currently Amended): A method for ameliorating LHRH analogue-induced reduction in bone density in a patient comprising administering to said patient one or more LHRH analogues and a-6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)-benzoyl]benzo[b]thiophene, or the hydrochloride salt thereof, wherein said one or more LHRH analogues and said 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)-benzoyl]benzo[b]thiophene, or the hydrochloride salt thereof, are administered sequentially or simultaneously.

54. (Previously Presented): A method of inhibiting LHRH analog-induced detrimental side effects due to the administration of an LHRH analog to a patient, wherein said detrimental side effect is reduction in bone density, comprising administering to a patient

in need thereof an effective amount of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]-thiophene.